Lucid Diagnostics (LUCD) Stock Statistics & Valuation Metrics

Lucid Diagnostics has a market cap or net worth of $107.92M. The enterprise value is $166.96M.

Lucid Diagnostics has 108,194,610 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lucid Diagnostics’s return on equity (ROE) is -8.45 and return on invested capital (ROIC) is -172.84%.

The current PE Ratio of Lucid Diagnostics is ―. Lucid Diagnostics’s PEG ratio is ―.

In the last 12 months, Lucid Diagnostics had revenue of 4.35M and earned -45.53M in profits. Earnings per share was -1.05.

In the last 12 months, operating cash flow was -23.03B and capital expenditures -609.00K, giving a free cash flow of -23.03B billion.

Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Lucid Diagnostics upcoming earnings date is Nov 17, 2025, After Close (Confirmed).

Lucid Diagnostics as a current ratio of 1.07, with Debt / Equity ratio of 350.46%

In the past 12 months, Lucid Diagnostics has paid 0.00 in taxes.

Lucid Diagnostics EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -0.90.

Lucid Diagnostics has $31.12B in cash and marketable securities with $27.55B in debt, giving a net cash position of -$3.57B billion.

Gross margin is -34.49%, with operating margin of -1059.64%, and net profit margin of -1047.61%.

The average price target for Lucid Diagnostics is $3.39, which is 11.43% higher than the current price. The consensus rating is Strong Buy